European Society for Medical Oncology: Latest Data Indicate New Care Standard in Advanced/Recurrent Endometrial Cancer - Results From the RUBY Trial
March 28, 2023
March 28, 2023
LUGANO, Switzerland, March 28 -- The European Society for Medical Oncology issued the following news release:
Adding immunotherapy to standard chemotherapy for first-line treatment of advanced or first recurrence of endometrial cancer significantly improves progression-free survival (PFS) compared to chemotherapy alone, with a promising early indication of improved overall survival (OS). These clinically meaningful results from the Phase 3 RUBY trial (ENGOT-EN6-NSGO/GOG3031) are the . . .
Adding immunotherapy to standard chemotherapy for first-line treatment of advanced or first recurrence of endometrial cancer significantly improves progression-free survival (PFS) compared to chemotherapy alone, with a promising early indication of improved overall survival (OS). These clinically meaningful results from the Phase 3 RUBY trial (ENGOT-EN6-NSGO/GOG3031) are the . . .